secwatch.observer — SEC 8-K summary
======================================

Issuer:     INCYTE CORP (INCY)
CIK:        0000879169
Form:       8-K
Filed at:   2021-09-28T23:59:59+00:00
Accession:  0001104659-21-120276
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Incyte elects Otis W. Brawley, M.D. to board effective Sept 27, 2021
--------------------------------------------------------------------

- Board size increased to nine; Dr. Brawley elected as director effective September 27, 2021.
- Dr. Brawley is Bloomberg Distinguished Professor of Oncology and Epidemiology at Johns Hopkins University.
- Previously Chief Medical and Scientific Officer of American Cancer Society (2007–2018).
- Will receive standard non-employee director compensation as described in 2021 proxy statement.
- Dr. Brawley also serves on boards of Lyell Immunopharma and PDS Biotechnology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/879169/000110465921120276/0001104659-21-120276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/879169/000110465921120276/tm2128728d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-120276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer